Abstract
ALLESAGA®TAPE is the first once-daily transdermal patch for treatment of allergic rhinitis in the world, which contains the second generation antihistamine drug, emedastine fumarate, as an active ingredient. As a result of the phase III comparative study for patients with seasonal allergic rhinitis, the emedastine patches 4mg and 8mg showed superiority to the placebo. The efficacy of the emedastine patch has been also confirmed in all time zones including nighttime to early morning likely by stable blood emedastine concentration. This article describes the formulation and clinical characteristics of ALLESAGA®TAPE.
